TLSI

Business Context and Reporting Period

Company: TriSalus Life Sciences, Inc. (TLSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: TriSalus is an oncology-focused medical technology company developing the PEDD infusion system (TriNav) for solid tumors and the investigational immunotherapeutic nelitolimod. The company operates as a single reporting segment within the United States.

Key Financial Metrics

Liquidity: Cash balances increased significantly to $56.6 million, driven by a public equity offering. The company maintains a $50.0 million credit facility with OrbiMed, with $35.0 million currently drawn.

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $1.5 million in Q1 2026, a reversal from a net loss of $10.4 million in Q1 2025. This shift was primarily driven by non-cash gains totaling $11.3 million from the change in fair value of contingent earnout liabilities ($7.4 million) and warrant/revenue base redemption liabilities ($3.9 million).
• Revenue and Margins: Revenue decreased slightly by 2.9% to $8.9 million due to commercial expansion dynamics. However, gross margin improved to 86.2% from 83.7% due to lower average costs per TriNav unit.
• Operating Expenses: Total operating expenses increased to $16.1 million from $15.0 million. Sales and marketing expenses rose 10.1% due to sales organization expansion, while R&D increased 6.5% largely due to stock-based compensation.
• Capital Structure: The company completed a public offering in February 2026, issuing approximately 11.2 million shares for net proceeds of $42.6 million. This significantly improved the balance sheet, turning stockholders' equity from a deficit of $33.9 million to a positive $12.8 million.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring operating losses for the foreseeable future due to investments in R&D and commercialization. The company is seeking partners to advance Phase II trials for nelitolimod due to capital costs.
• Debt Covenants: The company is subject to revenue-based covenants under its OrbiMed Credit Agreement. As of March 31, 2026, the company was in compliance with the Product Revenue Base requirement ($43.5 million trailing 12-month threshold), and no repayments were triggered.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to a continuing material weakness in accounting for significant transactions. Remediation efforts are underway but require more time to demonstrate effectiveness.
• Risks: Key risks include the ability to raise future financing, maintain reimbursement rates for TriNav (HCPCS codes), and the success of clinical trials for nelitolimod. The company also faces dilution risks from potential future equity issuances.

Investor Verification Checklist

• Non-Cash Gains: Verify the sustainability of the net income, which is heavily reliant on $11.3 million in non-cash fair value adjustments rather than core operating performance.
• Internal Control Weakness: Monitor the remediation status of the material weakness in internal controls over financial reporting, which remains unremediated as of the filing date.
• Debt Covenants: Track quarterly revenue performance against the OrbiMed Product Revenue Base thresholds ($43.5M, $46.0M, $50.0M) to assess the risk of mandatory debt repayment.
• Cash Burn: Review the cash burn rate from operating activities ($6.5 million used in Q1 2026) against the current cash balance ($56.6 million) to estimate runway without additional financing.
• Reimbursement Stability: Confirm the stability of CMS reimbursement codes (HCPCS C9797 and C8004) for the TriNav device, as revenue is sensitive to these rates.